MarketPulse
M

$MNPR

2 articles found
2 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Monopar Therapeutics Reports $137.5M Cash, Advances Wilson Disease Treatment

Monopar reports Q1 2026 results with $137.5M cash, $3.9M net loss. ALXN1840 shows superior efficacy in Phase 3 trial; FDA submission planned mid-2026.
MNPRFDA approvalNDA submission
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Monopar Strengthens Balance Sheet With $92M Raise, Eyes 2026 Drug Submission

Monopar reports $13.7M net loss, $140.4M cash reserves funding operations through 2027. Company plans mid-2026 NDA submission for Wilson disease treatment ALXN1840.
MNPRfinancial resultsFDA approval